Drug intelligence / Profile preview

REGE

Development stage: Unknown
Lead developer: National Center for Radiation Research and Technology
Administration: Topical

Overview

REGE is a biological product derived from human amniotic membrane extra-cellular matrix. It is utilized as a topical treatment and dressing to promote tissue regeneration and wound healing, particularly in conditions such as psoriasis and chronic skin ulcers associated with Epidermolysis Bullosa. It is manufactured by the National Center for Radiation Research and Technology, Egypt.

Brand names: REGE proREGE pro gel
Other names: human amniotic membrane extra-cellular matrixDried human amniotic membrane dressing

Beyond the preview

Go deeper on REGE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGE.

Explore the full profile